RET, ROS1 and ALK fusions in lung cancer
Nature Medicine2012Vol. 18(3), pp. 378–381
Citations Over TimeTop 1% of 2012 papers
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara, Young Lim Choi, Yukitoshi Satoh, Sakae Okumura, Ken Nakagawa, Hiroyuki Mano, Yuichi Ishikawa
Related Papers
- → Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer(2019)58 cited
- → ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor(2017)39 cited
- → Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma(2012)31 cited
- → 1262P ROS1 resistance mutations and co-occurring genetic alterations to the ROS1 protein-tyrosine kinase inhibitors (crizotinib) in lung cancer(2021)1 cited